Paper of the Month - November, 2010

0 rating

In vivo administration of hypomethylating agents mitigate graft-versus-host disease without sacrificing graft-versus-leukemia.



READER POLL

L&L poll 2
What do you consider to be the most exciting advances in therapeutics research in myeloid leukemia at present?






Powered by NetPolls

SUBMIT AN ARTICLE